{"retracted":false,"update":{"timestamp":1403136000000,"doi":"10.1007/s10549-014-3010-y","type":"correction"},"doi":"10.1007/s10549-014-2923-9","journal":"Breast Cancer Research and Treatment","publisher":"Springer Nature","title":"Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer"}
